Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dawn Meyer

Nurse Practitioner, Family San Diego, CA Nurse Practitioner

NPI 1467575126 CMS profile 11141098

200 W Arbor Dr, Mon 3Rd Floor Suite 3, San Diego, CA 92103

Open in the dashboard

General payments

$270,157

381 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dawn Meyer of San Diego, CA is reported in the CMS Open Payments database as having received $270,157 across 381 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,607 60
2024 General $44,230 67
2023 General $83,838 120
2022 General $67,963 109
2021 General $22,519 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dawn Meyer
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Dawn Meyer were reported at $51,607. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Dawn Meyer Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $22,519 $124 $35–$379 $132
2022 $67,963 $141 $44–$430 $149
2023 $83,838 $154 $49–$476 $160
2024 $44,230 $165 $51–$504 $164
2025 $51,607 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Chiesi USA, Inc. $231,206 277 payments
  2. AstraZeneca Pharmaceuticals LP $30,116 65 payments
  3. BTG International, Inc. $4,439 5 payments
  4. Alexion Pharmaceuticals, Inc. $3,747 11 payments
  5. Abbott Laboratories $223 18 payments
  6. Novartis Pharmaceuticals Corporation $108 1 payment
  7. Siemens Medical Solutions USA, Inc. $108 1 payment
  8. Viz.Ai, Inc. $105 1 payment
  9. Boston Scientific Corporation $76 1 payment
  10. CVRx, Inc. $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $142,084 78 payments
  2. Honoraria $48,500 25 payments
  3. Travel and Lodging $40,235 122 payments
  4. Consulting Fee $30,763 10 payments
  5. Food and Beverage $8,443 143 payments
  6. Education $133 3 payments
Products named General payments · program years 2021–2025
  1. CLEVIPREX $215,135 270 payments
  2. ANDEXXA Rare Disease $30,718 64 payments
  3. KENGREAL $4,013 5 payments
  4. Andexxa Hematology $3,117 10 payments
  5. ARTIS icono biplane $108 1 payment
  6. LEQVIO $108 1 payment
  7. Viz.AI LVO $105 1 payment
  8. WATCHMAN FLX $76 1 payment
  9. COROFLOW $75 10 payments
  10. Diamondback Coronary $61 3 payments
  11. Other $163 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$21,808

Medicare's payments for the services billed

Medicare patients

132

Average age 73

Services billed

223

68 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 52%
Arthritis 52%
Diabetes 49%
Heart failure 49%
Ischemic heart disease 44%
Chronic kidney disease 44%
Atrial fibrillation 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CLEVIPREX
  • CHIESI USA, INC. $37,655
$37,655 — —
KENGREAL
  • CHIESI USA, INC. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

381 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record